Lisa Nolan
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations.
Across 97 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$451
- AstraZeneca$263
- AbbVie$173
- Axsome Therapeutics, Inc.$160
- Lilly USA, LLC$152
- Bayer$124
- plus $596 from 15 others
What the payments were for
- Food & beverage$1,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $451 |
| AstraZeneca | 13 | $263 |
| AbbVie | 11 | $173 |
| Axsome Therapeutics, Inc. | 3 | $160 |
| Lilly USA, LLC | 10 | $152 |
| Bayer | 7 | $124 |
| Novartis | 5 | $85 |
| Merck | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Exact Sciences | 3 | $60 |
| GSK | 3 | $57 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Pfizer | 2 | $32 |
| Astellas Pharma US Inc | 2 | $31 |
| Amgen | 2 | $31 |
| Boehringer Ingelheim | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Organon | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$125
How this compares
$1,919 in reported general payments places this provider in the 65th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $61,129 |
| OzempicSemaglutide | 38 | $52,778 |
| FarxigaDapagliflozin Propanediol | 28 | $19,234 |
| EliquisApixaban | 20 | $15,546 |
| Mirabegron ErMirabegron | 11 | $3,354 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $815 |
| Montelukast Sodium | 68 | $726 |
| Bupropion XlBupropion Hcl | 30 | $645 |
| Gabapentin | 42 | $606 |
| Atorvastatin Calcium | 84 | $573 |
| Losartan Potassium | 52 | $541 |
| Tolterodine Tartrate | 14 | $518 |
| Levothyroxine Sodium | 63 | $488 |
| Tramadol Hcl | 50 | $465 |
| Escitalopram Oxalate | 43 | $440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $152 | $61,12949 claims |
| Novo NordiskOzempic | $451 | $52,77838 claims |
| AstraZenecaFarxiga | $263 | $19,23428 claims |
| PfizerEliquis | $32 | $15,54620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,490 medical providers in Texas.
Other medical in Hondo
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.